media – Page 542 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin)

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced publication of an article that demonstrated the Company’s proprietary ADAPT Biotargeting System™ (ADAPT) significantly out-performed standard HER2 testing in predicting response to trastuzumab (Herceptin®) for breast cancer patients.
- Source: Carislifesciences
- 846
- March 27, 2018
breast cancer Researches trastuzumab
TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn’s disease in Europe

First allogeneic stem cell therapy to receive central marketing authorization approval in Europe. Alofisel offers a new treatment option for patients who do not respond to current available therapies and may be subject to numerous invasive surgeries1
- Source: tigenix
- 601
- March 27, 2018
Alofisel EC New Approvals perianal fistulas Takeda
Lokelma approved in the EU for the treatment of adults with hyperkalaemia

AstraZeneca announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia. Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.
- Source: Worldpharmanews
- 578
- March 27, 2018
hyperkalaemia Lokelma New Approvals
Male birth control pill shows early promise, but will it work?

An attempt to develop a safe and effective "male pill" is making headway, according to preliminary results of a small study. In a four-week trial of men under 50, an experimental hormone-based birth control pill was found to be "well-tolerated."
- Source: cbsnews
- 558
- March 27, 2018
contraception male pill Researches
UCSD researchers develop wearable, 24-hour GI tract monitor

A wearable device, developed by researchers at the GI Innovation Group out of the University of California San Diego, can track electrical activity in the stomach over a 24-hour period. The device works similarly to how an ECG would work for the heart, but instead it monitors the electrical activities of gastrointestinal tract.
- Source: MobiHealthNews
- 551
- March 27, 2018
digital health New Approvals wearables
Shire & NanoMedSyn Enter Collaboration

Shire and NanoMedSyn have entered into a preclinical research collaboration to evaluate a potential ERT using NanoMedSyn's proprietary synthetic derivatives named AMFA.
- Source: Contract Pharma
- 508
- March 27, 2018
preclinical Researches Shire
Israel to Invest $275 Million in Digital Health Project

Israel approved a plan to invest 1 billion shekels ($275 million) to digitize the personal health records of its nearly 9 million citizens to help develop new drugs.
- Source: Bloomberg
- 570
- March 27, 2018
digital health Market Views
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) were published in the peer-reviewed journal The Lancet.
- Source: Novartis
- 537
- March 26, 2018
Clinical Trials SPMS
Big Events on Pharmaceuticals during NPC & CPPCC

The two sessions (NPC & CPPCC) this year have received much attention from China and outside China, wherein, the most-watched theme is “reform”. Regarding pharmaceuticals, the event that attracts the highest attention is CFDA reform, followed by policy moves of the TCM issue and bio-medicine, etc. that China has been strongly supporting in recent years.
- Source: EN-CPhI
- 1,122
- March 26, 2018
CFDA China CPhI pharmaceutical Policies
AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch

AbbVies stock $ABBV is getting hammered this morning after its $10 billion Rova-T program posted poor mid-stage results for third-line small cell lung cancer, forcing the company to scuttle any plans to seek an accelerated approval for the closely-watched drug after talks with skeptical regulators.
- Source: 4-traders
- 613
- March 26, 2018
AbbVies Clinical Trials Company Insights small cell lung cancer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.